A meta-analysis of low- density lipoprotein cholesterol, non-high-density lipoprotein choles- terol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes. 2011;4:337 45. S2.3-2. Grundy SM, Vega GL, Tomassini JE, et al. Correlation of non-high- density lipoprotein cholesterol and low-density lipoprotein choles- terol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial). Am J Cardiol. 2009;104:548 53. S2.3-3. Sniderman AD, Tremblay A, De Graaf J, et al. Phenotypes of hyper- triglyceridemia caused by excess very-low-density lipoprotein. J Clin Lipidol. 2012;6:427 33. S2.3-4. Grundy SM, Vega GL, Tomassini JE, et al. Comparisons of apoli- poprotein B levels estimated by immunoassay, nuclear magnetic resonance, vertical auto profile, and non-high-density lipoprotein cholesterol in subjects with hypertriglyceridemia (SAFARI Trial). Am J Cardiol. 2011;108:40 6. S2.3-5. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2016;68:92 125. S2.3-6. Tsimikas S. A Test in Context: Lipoprotein(a): diagnosis, progno- sis, controversies, and emerging therapies. J Am Coll Cardiol. 2017;69:692 711. S2.3-7. Cook NR, Mora S, Ridker PM. Lipoprotein(a) and cardiovascular risk prediction among women. J Am Coll Cardiol. 2018;72:287 96. 2.4. Monitoring Response of LDL-C to Statin Therapy S2.4-1. Cholesterol Treatment Trialist s (CTT) CollaborationBaigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26 randomised trials. Lancet. 2010;376:1670 81. S2.4-2. Boekholdt SM, Hovingh GK, Mora S, et al. Very low levels of ath- erogenic lipoproteins and the risk for cardiovascular events: a meta- analysis of statin trials. 